Main responsibilities of Laia Crespo will include the identification and assessment of investment and disinvestment opportunities from the scientific and business perspectives

Barcelona –September, 28, 2009 – Ysios Capital Partners (www.ysioscapital.com), a venture capital firm specialized in healthcare and biotechnology, appoints Laia Crespo as Investment Manager. With this additional incorporation Ysios strengthens the area of scientific and business analysis.

Laia Crespo will be in charge of analyzing the target companies of the fund from a scientific and business perspectives, providing all the necessary support to the decision making process as well as all her expertise in the pharmaceutical and biotechnology sector in order to define the investment and disinvestment strategies of the firm. The new investment manager will also be responsible for the scientific and business reporting to the Investment Committee, the council that determines the companies to invest in, and she will actively collaborate in the supervision of the portfolio companies.

Laia Crespo obtained a first degree in Chemistry at the University of Barcelona, where she also completed a Master in Science and a PhD working on the synthesis and biophysical characterization of peptides for drug delivery applications. Laia holds an MBA from Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance. In that period she collaborated with the Centre for Genomic Regulation in Barcelona and participated in projects related to the area of medical devices.

Laia Crespo developed her professional career primarily in the biotechnology cluster of Cambridge, UK, in companies such as Spirogen and Medivir. Prior to joining Ysios Laia assessed commercial and scientific licensing-in opportunities as part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group.

During her career, Laia Crespo has interacted with a large number of international pharmaceutical and biotechnology companies and she has also participated in the management and coordination of multiple research projects in a wide range of therapeutic areas reinforcing her analytical and management skills.

ABOUT YSIOS CAPITAL PARTNERS

Ysios Capital Partners is formed by a multidisciplinary team of eight professionals experts in venture capital and in the start-up and growth of healthcare and biotechnology companies. The partners of Ysios are Joël Jean-Mairet, former CEO of GLYCART Biotechnoloy AG; Julia Salaverría, former fund manager of Talde and Josep Lluís Sanfeliu, former Corporate Finance and Business Development executive of Almirall. In 2008, Ysios closed the largest biotech venture capital fund in Spain, Ysios BioFund I.

More information @ http://www.ysioscapital.com